Svas Biosana S.p.a. · MIL:SVS
Svas Biosana — NextGems Conference 2025
16 slides from Svas Biosana's conference presentation, October 2025
Slide 1: Investor Presentation – NextGems Conference 2025, Milano
Investor Presentation NextGems Conference 2025, Milano October 2025
Slide 2: Shareholders’ Structure & Geographical Presence
Shareholders’ Structure & Geographical Presence Shareholders (1) Geographical Presence Free Float and 21 Monte Others Somma S.r.l. 30,28% 43,86% (2) SVAS Biosana S.p.A. 5,72% Agrinvest S.r.l. 0,93% (3) Belforte S.r.l. 5,46% (3) Cofi Italia S.r.l. Umberto Perillo 8,19% (3) 5,56% (1) Updated to Octobe
Slide 3: Group Overview – Svas Biosana At a Glance
Group Overview SVAS Biosana Group (“SVAS”, the “Company” or the “Group”) is an Italian leading player in the medical devices and disposables sector, acting Svas Biosana «At a Glance» both as a manufacturer and as a distributor. Key Financial Highlights The Group was founded in Southern Italy in 1972
Slide 4: Group Overview – Geographical Presence and History
Group Overview Geographical Presence and History Warehouses and Offices ▪ Somma Vesuviana (NA) – 12.200 sqm: Chemical Microbiologic Division Division ❑ Site 1 (Via Trentola 7) Medical Devices in development Cosmetics Pharmaceutical ❑ Site 2 (Via Colle 104) Expertise Micro & Nanotechnology Bioenginee
Slide 5: Group Overview – Business Snapshot
Production & Group Overview Legend Sale Distribution & Business Snapshot Sale Company Activity Production Distribution Business €17,4m €4,9m €12,3m Mark €25,7m €11,6m Farmex Medical Svas Bormia Line(1) 24,20% 6,82% 17,11% Medical 35,74% 16,13% Incontinence Products Custom Packs & Specialist Disposab
Slide 6: Production – Main products
Production – Main products Farmex Medical Adult Incontinence Aids Custom Pack Standard Dressings Cotton Wool Advanced Dressings Surgical Suction Infusion and Systems Drainage Devices Svas Biosana Investor Presentation October 2025 6
Slide 7: Distribution – Main products
Distribution – Main products Specialties Cardiac Surgery Orthopedics and Arthroscopy Drug Transfer Devices for Peritoneal Dyalisis Cardiopulmonary TAVI Orthopedic Arthroscopy Implants Devices Anesthesia Products Implants and Equipment Radiology & Imaging Cardiology Laparoscopic Advanced Hemostatic C
Slide 8: Group Overview – 1H 2025 Sales Breakdown
Group Overview 1H 2025 Sales Breakdown By Activity By Geography By Customer Type Production Private 29% Customers 1H 2025 Foreign Sales1 ~ 25% 1H 2025 1H 2025 Countries Sales1 FY 2022 52% Sales1 Distribution 71% Italy 48 % Public Customers ~ 75% First-class Suppliers National Public Hospitals Public
Slide 9: Investment Highlights and Market Dynamics
Group Overview Investment Highlights and Market Dynamics 1. Rich and consolidated portfolio of products to satisfy chronic, 2. Qualified commercial structure and close relationship with medical operators medical and surgical healthcare needs generate additional value while creating high entry barrie
Slide 10: Financial Data – Key Financial Highlights
Financial Data Key Financial Highlights Millions of Euro EBITDA 15,3 Millions of Euro Net Revenue 16,00 € 30,00% Millions of Euro 2022A 2023A 2024A 1H 2024 1H 2025 120,3 14,2 118,3 14,00 € 120,00 € 11,9 25,00% Net Revenue 97,2 118,3 120,3 58,2 70,4 97,2 12,00 € 10,6 100,00 € YoY Δ 19,9% 21,7% 1,7% 2
Slide 11: Annex – Group Structure and Board of Directors
Annex Group Structure Absolute majority of shares owned by Umberto Perillo Free Float and 21 Monte Umberto Svas Biosana Others Agrinvest S.r.l. Cofi Italia S.r.l. Belforte S.r.l. Board of Directors Somma S.r. 𝑙..(1) Perillo S.p.A. 43,86% 5,56% 5,72% 0,93% 8,19% 5,46% 30,28% Filippo Maraniello…
Slide 12: Annex – 1H Consolidated Income Statement
Annex 1H Consolidated Income Statement 30/06/2025 % 30/06/2024 % Delta % Revenues from sales and service 70.424.155 100,00% 58.185.142 100,00% 12.239.013 21,03% External Costs 54.376.434 77,21% 44.226.766 76,01% 10.149.668 22,95% Added Value 16.047.721 22,79% 13.958.376 23,99% 2.089.345 14,97% Cost
Slide 13: Annex – 1H Consolidated Balance Sheet
Annex 1H Consolidated Balance Sheet 30/06/2025 31/12/2024 Delta Net Intangible fixed assets 17.812.178 11.936.115 5.876.063 Net Tangible Fixed Assets 27.075.319 27.114.307 (38.988) Equity investments and other financial fixed assets 110.179 110.179 0 Fixed Capital 44.997.676 39.160.601 5.837.075 Inv
Slide 14: Annex – Consolidated Income Statement
Annex Consolidated Income Statement 31/12/2024 % 31/12/2023 % Delta % Revenues from sales and service 120.314.867 100,0% 118.283.990 100,0% 2.030.877 1,7% External Costs 92.562.304 76,9% 93.635.659 79,2% (1.073.355) -1,1% Added Value 27.752.563 23,1% 24.648.331 20,8% 3.104.232 12,6% Cost of labor 14
Slide 15: Annex – Consolidated Balance Sheet
Annex Consolidated Balance Sheet 31/12/2024 31/12/2023 Delta Net Intangible fixed assets 11.936.115 11.419.565 516.550 Net Tangible Fixed Assets 27.114.307 26.774.269 340.038 Equity investments and other financial fixed assets 110.179 110.179 - Fixed Capital 39.160.601 38.304.013 856.588 Inventory 3
Slide 16: Legal Disclaimer
Legal Disclaimer Legal Disclaimer For the purposes of this disclaimer, this presentation (the “Presentation”) comprises the attached slides and any materials distributed at, or in connection with, the Presentation. The Presentation has been prepared bY Svas Biosana S.p.A. (the “Company”) solely for